Tumoren und Pseudotumoren der Netzhaut und des Ziliarepithels

Eva Biewald; Sabrina Schlüter; Tobias Kiefer; Sami Dalbah; Norbert Bornfeld; Nikolaos E. Bechrakis

doi:10.1055/a-1229-0946

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2020; 237(11): 1359-1378
DOI: 10.1055/a-1229-0946

CME-Fortbildung

Tumoren und Pseudotumoren der Netzhaut und des Ziliarepithels

Tumors and Pseudotumors of the Retina and the Ciliary Epithelium

Eva Biewald

,

Sabrina Schlüter

,

Tobias Kiefer

,

Sami Dalbah

,

Norbert Bornfeld

,

Nikolaos E. Bechrakis

Abstract

Zusammenfassung

Die Varietät retinaler Tumoren reicht von harmlosen Läsionen über benigne, lokal destruierende Tumoren bis hin zu lebensbedrohlichen Erkrankungen. Nicht immer lassen sie sich einfach voneinander unterscheiden. Die Diagnose sollte nach Möglichkeit klinisch gestellt werden wegen der Gefahr einer Tumorzellverschleppung durch invasive Diagnostik. Jedoch rückt die genetische Charakterisierung der Läsion immer mehr in den Vordergrund. Je nach Entität ist eine Therapie in einem spezialisierten Zentrum notwendig.

Abstract

The variety of retinal tumors ranges from harmless lesions to benign, locally destructive tumors and life-threatening diseases, and they are not always easy to distinguish from each other. The differential diagnosis includes real neoplasia, reactive inflammatory pathologies and vascular anomalies of the fundus as well. If possible, the diagnosis should be made clinically in order to avoid the danger of tumor cell spread via invasive diagnostic tools. Nevertheless, genetic analysis of the pathology is gaining more importance and adds to the precise characterization of the diagnosis. Depending on the tumor entity, therapy in a specialized center is necessary.

Schlüsselwörter

Retinoblastom - Morbus Coats - retinale Angiome - vasoproliferative Tumoren - kombiniertes Hamartom der Retina und des retinalen Pigmentepithels (CRPEH)

Key words

retinoblastoma - Coatsʼ disease - retinal angiomas - vasoproliferative tumors - congenital hypertrophy of retinal pigment epithelium (CRPEH)

Full Text

References

Literatur
1 Dimaras H, Corson TW, Cobrinik D. et al. Retinoblastoma. Nat Rev Dis Primers 2015; 1: 15021 doi:10.1038/nrdp.2015.21
2 Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am 2005; 18: 41-53 viii doi:10.1016/j.ohc.2004.11.003
3 Lohmann D. Retinoblastoma. Adv Exp Med Biol 2010; 685: 220-227 doi:10.1007/978-1-4419-6448-9_21
4 Biewald E, Holdt M, Bornfeld N. Neue Therapiestrategien beim Retinoblastom: Nichtsystemische Chemotherapie. Ophthalmologe 2014; 111: 379-382 doi:10.1007/s00347-014-3038-8
5 Temming P, Arendt M, Viehmann A. et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer 2017; 64: 71-80 doi:10.1002/pbc.26193
6 Bechrakis NE, Bornfeld N, Schueler A. et al. Clinicopathologic features of retinoblastoma after primary chemoreduction. Arch Ophthalmol 1998; 116: 887-893 doi:10.1001/archopht.116.7.887
7 Shields CL, Mashayekhi A, Au AK. et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113: 2276-2280 doi:10.1016/j.ophtha.2006.06.018
8 Pekacka A. The Role of Intraarterial Chemotherapy in the Management of Retinoblastoma. J Ophthalmol 2020; 2020: 3638410 doi:10.1155/2020/3638410
9 Manjandavida FP, Stathopoulos C, Zhang J. et al. Intra-arterial chemotherapy in retinoblastoma – A paradigm change. Indian J Ophthalmol 2019; 67: 740-754 doi:10.4103/ijo.IJO_866_19
10 Biewald EM, Bornfeld N, Metz KA. et al. Histopathology of retinoblastoma eyes enucleated after intra-arterial chemotherapy. Br J Ophthalmol 2019;
11 Suzuki S, Aihara Y, Fujiwara M. et al. Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol 2015; 59: 164-172 doi:10.1007/s10384-015-0378-0
12 Munier FL, Gaillard MC, Balmer A. et al. Intravitreal chemotherapy for vitreous seeding in retinoblastoma: Recent advances and perspectives. Saudi J Ophthalmol 2013; 27: 147-150 doi:10.1016/j.sjopt.2013.06.003
13 Francis JH, Brodie SE, Marr B. et al. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience. Ophthalmology 2017; 124: 488-495 doi:10.1016/j.ophtha.2016.12.015
14 Sen M, Shields CL, Honavar SG. et al. Coats disease: An overview of classification, management and outcomes. Indian J Ophthalmol 2019; 67: 763-771 doi:10.4103/ijo.IJO_841_19
15 Robitaille JM, Zheng B, Wallace K. et al. The role of Frizzled-4 mutations in familial exudative vitreoretinopathy and Coats disease. Br J Ophthalmol 2011; 95: 574-579 doi:10.1136/bjo.2010.190116
16 Statland JM, Sacconi S, Farmakidis C. et al. Coats syndrome in facioscapulohumeral dystrophy type 1: frequency and D4Z4 contraction size. Neurology 2013; 80: 1247-1250 doi:10.1212/WNL.0b013e3182897116
17 Daruich AL, Moulin AP, Tran HV. et al. Subfoveal nodule in coatsʼ disease: Toward an updated classification predicting visual prognosis. Retina 2017; 37: 1591-1598 doi:10.1097/IAE.0000000000001399
18 Kase S, Rao NA, Yoshikawa H. et al. Expression of vascular endothelial growth factor in eyes with Coatsʼ disease. Invest Ophthalmol Vis Sci 2013; 54: 57-62 doi:10.1167/iovs.12-10613
19 Kusaka S. Surgical management of coats disease. Asia Pac J Ophthalmol (Phila) 2018; 7: 156-159 doi:10.22608/APO.201867
20 Kaliki S, Taneja S, Palkonda VAR. Inadvertent intraocular surgery in children with unsuspected retinoblastoma: a study of 14 cases. Retina 2019; 39: 1794-1801 doi:10.1097/IAE.0000000000002214
21 Soliman SE, Wan MJ, Heon E. et al. Retinoblastoma versus advanced Coatsʼ disease: Is enucleation the answer?. Ophthalmic Genet 2017; 38: 291-293 doi:10.1080/13816810.2016.1199715
22 Hiscott P, Mudhar H. Is vasoproliferative tumour (reactive retinal glioangiosis) part of the spectrum of proliferative vitreoretinopathy?. Eye 2009; 23: 1851-1858 doi:10.1038/eye.2008.351
23 Anastassiou G, Bornfeld N, Schueler AO. et al. Ruthenium-106 plaque brachytherapy for symptomatic vasoproliferative tumours of the retina. Br J Ophthalmol 2006; 90: 447-450 doi:10.1136/bjo.2005.081422
24 Hussain RN, Jmor F, Damato B. et al. Verteporfin photodynamic therapy for the treatment of retinal vasoproliferative tumors. Ophthalmology 2015; 122: 2361-2363 doi:10.1016/j.ophtha.2015.05.026
25 Saito W, Kase S, Fujiya A. et al. Expression of vascular endothelial growth factor and intravitreal anti-VEGF therapy with bevacizumab in vasoproliferative retinal tumors. Retina 2013; 33: 1959-1967 doi:10.1097/IAE.0b013e3182923490
26 Smith J, Steel D. The surgical management of vasoproliferative tumours. Ophthalmologica 2011; 226 Suppl 1: 42-45 doi:10.1159/000328209
27 Binderup MLM, Stendell AS, Galanakis M. et al. Retinal hemangioblastoma: prevalence, incidence and frequency of underlying von Hippel-Lindau disease. Br J Ophthalmol 2018; 102: 942-947 doi:10.1136/bjophthalmol-2017-310884
28 Latif F, Tory K, Gnarra J. et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320 doi:10.1126/science.8493574
29 Richards FM, Payne SJ, Zbar B. et al. Molecular analysis of de novo germline mutations in the von Hippel-Lindau disease gene. Hum Mol Genet 1995; 4: 2139-2143 doi:10.1093/hmg/4.11.2139
30 Schmid S, Gillessen S, Binet I. et al. Management of von Hippel-Lindau disease: an interdisciplinary review. Oncol Res Treat 2014; 37: 761-771 doi:10.1159/000369362
31 Singh AD, Nouri M, Shields CL. et al. Treatment of retinal capillary hemangioma. Ophthalmology 2002; 109: 1799-1806 doi:10.1016/s0161-6420(02)01177-6
32 Gaudric A, Krivosic V, Duguid G. et al. Vitreoretinal surgery for severe retinal capillary hemangiomas in von hippel-lindau disease. Ophthalmology 2011; 118: 142-149 doi:10.1016/j.ophtha.2010.04.031
33 Bornfeld N, Kreusel KM. Kapilläre Hämangiome der Netzhaut beim Von-Hippel-Lindau-Syndrom. Neue Therapieansätze. Ophthalmologe 2007; 104: 114-118 doi:10.1007/s00347-007-1485-1
34 Kreusel KM, Bornfeld N, Lommatzsch A. et al. Ruthenium-106 brachytherapy for peripheral retinal capillary hemangioma. Ophthalmology 1998; 105: 1386-1392 doi:10.1016/S0161-6420(98)98017-4
35 Garcia-Arumi J, Sararols LH, Cavero L. et al. Therapeutic options for capillary papillary hemangiomas. Ophthalmology 2000; 107: 48-54 doi:10.1016/s0161-6420(99)00018-4
36 Hussain RN, Jmor F, Damato B. et al. Verteporfin photodynamic therapy for the treatment of sporadic retinal capillary haemangioblastoma. Photodiagnosis Photodyn Ther 2015; 12: 555-560 doi:10.1016/j.pdpdt.2015.10.008
37 Magee MA, Kroll AJ, Lou PL. et al. Retinal capillary hemangiomas and von Hippel-Lindau disease. Semin Ophthalmol 2006; 21: 143-150 doi:10.1080/08820530500350712
38 Heimann H, Damato B. Congenital vascular malformations of the retina and choroid. Eye 2010; 24: 459-467 doi:10.1038/eye.2009.310
39 Hewick S, Lois N, Olson JA. Circumferential peripheral retinal cavernous hemangioma. Arch Ophthalmol 2004; 122: 1557-1560 doi:10.1001/archopht.122.10.1557
40 Holdt M, Jurklies C, Schueler A. et al. Intraokulare Medulloepitheliome – klinische Serie mit 10 Fällen. Klin Monatsbl Augenheilkd 2009; 226: 1017-1022 doi:10.1055/s-0028-1109944
41 Zimmerman LE. Verhoeffʼs “terato-neuroma”. A critical reappraisal in light of new observations and current concepts of embryonic tumors. The Fourth Frederick H. Verhoeff Lecture. Am J Ophthalmol 1971; 72: 1039-1057
42 Tadepalli SH, Shields CL, Shields JA. et al. Intraocular medulloepithelioma – A review of clinical features, DICER 1 mutation, and management. Indian J Ophthalmol 2019; 67: 755-762 doi:10.4103/ijo.IJO_845_19
43 Shields JA, Shields CL. Glial tumors of the retina. The 2009 King Khaled Memorial Lecture. Saudi J Ophthalmol 2009; 23: 197-201 doi:10.1016/j.sjopt.2009.10.003
44 Rowley SA, OʼCallaghan FJ, Osborne JP. Ophthalmic manifestations of tuberous sclerosis: a population based study. Br J Ophthalmol 2001; 85: 420-423 doi:10.1136/bjo.85.4.420
45 Toteberg-Harms M, Sturm V, Sel S. et al. Retinal astrocytomas: long-term follow- up. Klin Monatsbl Augenheilkd 2011; 228: 337-339 doi:10.1055/s-0031-1273228
46 Good WV, Erodsky MC, Edwards MS. et al. Bilateral retinal hamartomas in neurofibromatosis type 2. Br J Ophthalmol 1991; 75: 190 doi:10.1136/bjo.75.3.190
47 Cohen VM, Shields CL, Furuta M. et al. Vitreous seeding from retinal astrocytoma in three cases. Retina 2008; 28: 884-888 doi:10.1097/IAE.0b013e3181669781
48 Shields JA, Eagle RC, Shields CL. et al. Aggressive retinal astrocytomas in 4 patients with tuberous sclerosis complex. Arch Ophthalmol 2005; 123: 856-863 doi:10.1001/archopht.123.6.856
49 Bornfeld N, Messmer EP, Theodossiadis G. et al. Giant cell astrocytoma of the retina. Clinicopathologic report of a case not associated with Bournevilleʼs disease. Retina 1987; 7: 183-189
50 Singh AD, Soto H, Bellerive C. et al. Reactive retinal astrocytic tumor (focal nodular gliosis): report of the clinical spectrum of 3 cases. Ocul Oncol Pathol 2017; 3: 235-239 doi:10.1159/000455151
51 Shields JA, Bianciotto CG, Kivela T. et al. Presumed solitary circumscribed retinal astrocytic proliferation: the 2010 Jonathan W. Wirtschafter Lecture. Arch Ophthalmol 2011; 129: 1189-1194 doi:10.1001/archophthalmol.2011.211
52 Shields CL, Materin MA, Marr BP. et al. Resolution of exudative retinal detachment from retinal astrocytoma following photodynamic therapy. Arch Ophthalmol 2008; 126: 273-274 doi:10.1001/archophthalmol.2007.54
53 Ramasubramanian A, Shields CL, Kytasty C. et al. Resection of intraocular tumors (partial lamellar sclerouvectomy) in the pediatric age group. Ophthalmology 2012; 119: 2507-2513 doi:10.1016/j.ophtha.2012.06.044
54 Marciano S, Mutolo MG, Siracusano M. et al. Everolimus for retinal astrocytic hamartomas in tuberous sclerosis complex. Ophthalmol Retina 2018; 2: 257-260 doi:10.1016/j.oret.2017.08.005
55 Gass JD. An unusual hamartoma of the pigment epithelium and retina simulating choroidal melanoma and retinoblastoma. Trans Am Ophthalmol Soc 1973; 71: 171-183 discussions 184–185
56 Dedania VS, Ozgonul C, Zacks DN. et al. Novel classification system for combined hamartoma of the retina and retinal pigment epithelium. Retina 2018; 38: 12-19 doi:10.1097/IAE.0000000000001499
57 Grant EA, Trzupek KM, Reiss J. et al. Combined retinal hamartomas leading to the diagnosis of neurofibromatosis type 2. Ophthalmic Genet 2008; 29: 133-138 doi:10.1080/13816810802206507
58 Cohn AD, Quiram PA, Drenser KA. et al. Surgical outcomes of epiretinal membranes associated with combined hamartoma of the retina and retinal pigment epithelium. Retina 2009; 29: 825-830 doi:10.1097/IAE.0b013e31819b1788
59 Regillo CD, Eagle Jr RC, Shields JA. et al. Histopathologic findings in congenital grouped pigmentation of the retina. Ophthalmology 1993; 100: 400-405 doi:10.1016/s0161-6420(93)31635-0
60 Shields CL, Materin MA, Walker C. et al. Photoreceptor loss overlying congenital hypertrophy of the retinal pigment epithelium by optical coherence tomography. Ophthalmology 2006; 113: 661-665 doi:10.1016/j.ophtha.2005.10.057
61 Rehan S, Aye K. In patients with a positive family history of familial adenomatous polyposis can the condition be diagnosed from the presence of congenital hypertrophy of the retinal pigment epithelium detected via an eye examination: A systematic review. Clin Exp Ophthalmol 2020; 48: 98-116 doi:10.1111/ceo.13643
62 Trichopoulos N, Augsburger JJ, Schneider S. Adenocarcinoma arising from congenital hypertrophy of the retinal pigment epithelium. Graefes Arch Clin Exp Ophthalmol 2006; 244: 125-128 doi:10.1007/s00417-005-0011-x